Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
What fits your routine
CrossRef G2E3 Suppresses the TumorKilling Function of CD8+ T Cells in Hepatocellular Carcinoma by Boosting CLCN2 Ubiquitination Fan Zhou, Ting Chen, Xingguo Tan, Jun Yu, Mengzhi Xiao, Jun Guo The FASEB Journal .2026;[Epub] CrossRef Tumor burden score determines survival benefit of anatomic resection in hepatocellular carcinoma: A multicenter propensity-matched study Shujie Pang, Yang Shi, Minjun Jiang, Qingwang Ye, Xin Yan, Zhe Sun, Xingrui Kou, Xiaoxiang Chen, Hui SiMa, Yiming Chen, Yingcheng Yang, Ning Yang European Journal of Surgical Oncology .2026
Global, regional, and national sepsis incidence and mortality, 19902017: analysis for the global burden of disease study
Wegovy is expected to show 50%+ reduction based on SELECT trial data for cardiovascular outcomes
Who should not use AOD-9604
US$ 21.04
US$ 25.62
US$ 20.78
US$ 28.41
US$ 21.04
